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Background: The aim of this study was to evaluate apoptotic (Bcl-2, Bax expression, caspase-3 activity, and
cytochrome-c) and angiogenic (MMP-9 levels and VEGF expression) markers in operable rectal cancer patients who
were treated with preoperative chemoradiotherapy (CRT) followed by total mesorectal excision (TME).
Understanding these factors will facilitate the identification of potential pathological responders before treatment,
leading to better local control and survival rates.
Methods: Between March 2006 and March 2008, 29 patients withTNM Stage III (cT3 N+) mid or low rectal cancer
were included in this study. Our sample consisted of 17 males (58.6%) and 12 females (41.4%). The median age was
60 years (range 24-88 years). Biopsy samples were taken from different portions of the tumors using flexible
endoscopy before neoadjuvant CRT. Preoperatively, all patients received radiation (45-50.4 gray (Gy) in 25 cycles
with concurrent 5-florouracil (5-FU) chemotherapy.
Results: A complete response was observed in 7 of 29 patients (24%). Bax staining was negative in 1 of the 7
patients (14%) in the pathological complete response (PCR) group and in 18 of the 22 patients (82%) in the no
pathological complete response (noPCR) group (p = 0.001). MMP-9 and VEGF levels were higher in the noPCR
group than the PCR group (p = 0.04, p = 0.05 respectively). No statistically significant differences were found
between VEGF and MMP-9 levels in nodal downstaging. No statistically significant relationships were found
between the other apoptotic factors (Bcl 2, cytochrome-c, and caspase-3 activity) and pathological response rate
(p > 0.05).
Conclusion: In neoadjuvant CRT patients, high levels of Bax expression and low levels of VEGF and MMP-9
expression on preoperative biopsies indicate that the patient will potentially be a good pathological responder.
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Rectal cancer (RC) is a major health problem and one of
the leading causes of cancer-related death worldwide [1].
In a new multidisciplinary study of mid- and distal rectal
cancer management modalities, neoadjuvant chemora-
diotherapy (CRT) or radiotherapy (RT) was used for
clinically staged T3/T4 and N + patients [2]. However,
the primary treatment modality for patients with rectal
cancer is surgery. Preoperative CRT offers a number of* Correspondence: atillakurt@yahoo.com
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reproduction in any medium, provided the orbenefits, such as tumor volume reduction, tumor down-
staging, more tumor resectability, a high rate of anal
sphincter preservation, a low local recurrence rate, and
improved survival [2,3]. However, a significant percent-
age of patients respond poorly to neoadjuvant CRT [3].
A pathologic complete response (PCR), characterized
by the sterilization of all tumor cells in the resected spe-
cimen, is one of the best surrogate markers of an excel-
lent prognosis [4-8]. Approximately 15-30% of patients
will experience a PCR, whereas the majority of patients
will have some degree of residual disease after CRT
[4,5].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tional results after surgery by decreasing the mean rest-
ing anal canal pressure and causing internal sphincter
fibrosis [9], and it can also have a negative effect on sexual
functioning in both genders [10]. Long-term bowel dys-
function is more prevalent in irradiated patients than in
patients who underwent surgery alone [11]. In addition,
rectal cancer patients treated with neoadjuvant radiother-
apy have an increased risk of secondary cancer [12]. Thus,
if patients with tumors that are highly responsive to CRT
could be identified at the time of diagnosis, then preopera-
tive CRT could be administered in a more selective and
individualized manner.
Apoptosis is directly related to tumor pathogenesis
and progression in rectal cancer. Treatment modalities
such as RT may induce apoptosis in rectal tumors.
Angiogenesis also plays a major role in cancer pathogen-
esis [13-15]. In solid tumors, angiogenesis is closely
associated with the over-expression of VEGF in tumor
cells [16]. Thus, evaluating apoptosis and angiogenesis
will facilitate the identification of rectal cancer patients
who may benefit from neoadjuvant therapy.
Several markers have been proposed as predictors of
the radio- and chemosensitivity of rectal cancers, includ-
ing Bcl-2, Bax, epidermal growth factor receptor (EGFR),
cyclooxygenase 2 (COX 2), microsatellite instability
(MIS), mismatch repair (MMR) genes, Ku-70, Ki-67, vas-
cular endothelial growth factor (VEGF), apoptotic rate,
proliferative index, and global gene expression [5,17]. To
date, however, no marker reliably predicts tumor CRT
response in clinical practice.
The aim of this study was to evaluate the effects of
apoptotic (Bcl-2, Bax, caspase-3, and cytochrome-c
expression) and angiogenic (MMP-9 levels and VEGF
expression) factors on the oncological outcomes of mid-
and distal rectal cancer patients managed with preopera-
tive CRT followed by total mesorectal excision (TME).
An understanding of these factors may allow potential
pathological responders to be identified before treatment




Between March 2006 and March 2008, 91 rectal cancer
patients were assessed preoperatively at the Istanbul
University, Istanbul Faculty of Medicine, Department of
General Surgery. All data were collected and recorded
prospectively, and the clinical and pathological features
were reviewed retrospectively. The study was approved by
the Ethics Committee of the Istanbul University Faculty of
Medicine. Informed consent was obtained from all patients.
Patient treatment was planned by a multidisciplinary
team, including surgeons, medical oncologists, radiationoncologists, pathologists and radiologists. Sixty-two
patients were excluded for meeting one or more of the
following criteria: proximal localization of the tumor
(n = 22, 35%), synchronous tumors (n = 5, 8%), polyposis
coli (n = 2, 3%), urgent operation (n = 4, 6%), peritonitis
carcinomatosa (n = 1,%1), systemic metastasis (n = 3,
4%), surgery performed at another center (n = 2, 3%),
unavailable or inadequate pretreatment archival biopsy
specimens (n = 3, 4%), refusal to take part in the study
(n = 15, 24%), and early stage diagnosis without pre-
operative CRT (n = 5, 8%). After excluding these 62
patients, 29 remaining patients were included in the
study. The inclusion criteria included biopsy-proven
adenocarcinoma of the mid or low rectum, clinical or
radiological evidence of a T3 or T4 tumor and lymph
node metastasis (cTNM, Stage III). The preoperative
work-up included a general clinical examination, a
digital rectal examination, a complete blood count, a
blood chemistry profile, a carcinoembryonic antigen
(CEA) assessment, a rigid proctosigmoidoscopy, a total
colonoscopy, a tumor biopsy, computed tomography
(CT) of the abdomen and a chest x-ray. Endorectal coil
or pelvic phase array magnetic resonance imaging
(MRI) and CT of the thorax were routinely used to
i mprove preoperative staging to select patients who
were candidates for preoperative CRT. Biopsy samples
were taken from different parts of the tumors using
flexible endoscopy. These samples were frozen and
preserved at -80°C.
Preoperative chemoradiotherapy
As is standard at our institution all patients received pre-
operative radiotherapy (180 cGy per day, 5 days per week
in 25 fractions over a period of 5 weeks for a total of
4,500 c-Gy) with concurrent chemotherapy (5-fluorouracil
225 mg/m2 per day, 1 infusion for 5 days per week over a
period of 5 weeks). The fields extended from the L5/S1
level superiorly to the bottom of the obturator foramina
inferiorly with a 1- to 1.5-cm margin on the bony pelvic
inlet. Surgical resection with curative intent was under-
taken 8 weeks after the completion of CRT.
Surgery
Twenty-nine cTNM stage III mid- or distal rectal cancer
patients underwent potentially curative surgery accord-
ing to the principles of TME described by Heald [18].
Sphincter-preserving surgery (SPS) was performed in 22
patients (76%), and 17 of these surgeries (77%) were per-
formed laparoscopically. Abdominoperineal resection
(APR) was performed in 7 patients (24%), and 4 (57%)
of these procedures were performed laparoscopically.
All patients were operated by the same surgeon (O.A)
who is specialized on laparoscopy and colorectal
cancer treatment. Histopathological examination of the
Kurt et al. BMC Clinical Pathology 2012, 12:27 Page 3 of 7
http://www.biomedcentral.com/1472-6890/12/27operative specimens was performed according to the
principles of Quirke et al. [19]. All the specimens
were examined by the same pathologist (V.O). The
pathology report included tumor staging according to
the American Joint Committee on Cancer TNM sta-
ging system (6th ed.) [20].
Laboratory methods
Biopsy samples were fixed in 10% buffered formalin for
1 week. Five-to-seven micron thick sections cut from
routinely prepared paraffin blocks were stained with
H&E and examined under a light microscope. Additional
sections placed on positively charged slides were utilized
for immunohistochemical examination. After deparaffi-
nization, microwave antigen retrieval was performed.
Thereafter, the Peroxi-Block (Ultra V block) TP 125 – HL
Lab Vision Corporation Fremont, California USA process
was performed, and the Primary Monoclonal Mouse
Antibody to BaxW (PDM 103 clone 2D2 ready-to-use;
Diagnostic Biosystems California USA) and Bcl-2W (PDM
106 clone 124; Diagnostic Biosystems California USA)
were utilized. Nuclear staining was performed with
hematoxylin. To determine staining density, 100 cells were
counted in 3 different areas under high magnification,
and based on the number of cells that were positively
stained, <10% was defined as negative and >10% was
defined as positive.
The MMP-9 assay was performed with a Human
MMP-9 ELISA kit (Bender MedSystems GmbH, Vienna,
Austria). The cytochrome-c and VEGF assays were
performed with BioSourceW ELISA kits (Invitrogen
Corporation, CA, USA). Caspase-3 activity was mea-
sured using ApoTarget™ colorimetric caspase-3 kitW
(Invitrogen Corporation, CA, USA). P-nitroaniline, pro-
duced by the enzymatic hydrolysis of acetyl Asp-Glu-
Val-Asp p-nitroaniline (Ac-DEVD-pNA), was measured
using a p-nitroaniline norm at 405 nm and a molar ab-
sorptivity (10,500 M-1 cm-1) coefficient. The endoscopic
tissue homogenate was centrifuged at 15,000 × g for
5 min at 4°C. The supernatant was added to the ELISA
plate, and after incubation at 37°C for 2 hours, the
absorbance was measured at 405 nm. The amount of
p-nitroaniline was calculated using an extinction coeffi-
cient and a standard curve after removing the absorb-
ance values of cells treated with caspase-3 substrate and
caspase-3 inhibitor. Enzyme activity was calculated as
milligrams of protein per minute according to the
amount of p-aniline released. Protein assays were per-
formed using the bicinchoninic acid method.
Assessment of pathological responses to preoperative
CRT
The response to preoperative CRT was assessed at the
pretreatment clinical stage rather than the final pathologicstage. PCR was defined as the absence of any residual can-
cer cells in the specimen (ypT0N0). Regressive changes,
including the extent of fibrosis and the amount of tumor
remaining in the resected specimen, were assessed on
H&E-stained slides. The pathologic response to pre-
operative CRT (tumor regression grade, TRG) was
scored based on the grading classification described by
Dworak et al. [21]: Grade 0 = no regression; Grade 1 =
minimal regression, dominant tumor mass with obvious
fibrosis and/or vasculopathy; Grade 2 = moderate re-
gression, dominantly fibrotic changes with tumor cells
or groups (easy to find); Grade 3 = good regression,
very few (difficult to find microscopically) tumor cells
in fibrotic tissue with or without mucous substance;
and Grade 4 = total regression, no tumor cells, only
fibrotic mass.
In this study, the group with Dworak [21] scores of
0 to 3 (partial responders or no responders, no PCR)
were compared with the group with Dworak scores of 4
(complete responders, PCR).
Statistical analysis
Differences between continuous variables were tested
using either Student’s t test or the Wilcoxon Rank Sum
Test. For categorical data, the summary statistics con-
sisted of proportions, and comparisons were performed
with either the Chi-squared Test or Fisher’s Exact Test.
The cumulative probabilities of overall survival (OS)
and disease-free survival (DFS) were estimated with
Kaplan-Meier survival methods, and differences be-
tween subgroups were assessed with the log rank test.
The duration of follow-up was calculated as the time
from surgery to the event of interest. Patients without
events of interest were assigned the date of the last
follow-up visit. In cases of local or distant metastasis,
the event was recorded and computed at its time of oc-
currence. To better assess the oncological implications
of PCR, the Cox proportional hazards model was used
to adjust the hazard ratios and corresponding 95% con-
fidence intervals. Statistical significance was set at 5%
(p < 0.05). The data were analyzed using the SPSS Pro-




The sample included 29 patients (17 males [58.6%] and
12 females [41.4%]) who underwent neoadjuvant CRT
followed by TME for stage cT3N +mid or low rectal
cancer. The median age was 60 years (range 24-88). The
distance from the anal verge was less than 5 cm in 13
patients (45%) and between 5.1 and 10 cm in 16 patients
(55%). Upon gross pathological examination, the median
tumor size was 30 mm (range 20-60 mm).
Kurt et al. BMC Clinical Pathology 2012, 12:27 Page 4 of 7
http://www.biomedcentral.com/1472-6890/12/27Histopathological examination
Histopathological examination revealed that the differenti-
ation of the adenocarcinoma was moderate in 25 patients
(86%). Tumor regression was staged based on the scale
described by Dworak: TRG 1, 5 patients (17%); TRG 2, 9
patients (31%); TRG 3, 8 patients (27%); and TRG 4, 7
patients (24%). Thus, PCR was achieved in 7 patients
(24%), and noPCR was achieved in 22 patients (76%). No
statistically significant difference was found between the
PCR and noPCR groups in terms of age, sex, tumor dis-
tance from the anal verge, tumor localization, operation
type or total number of harvested lymph nodes (p > 0.05).
Association of apoptotic and angiogenic markers and
response to CRT
Bax expression was statistically significant for T staging
(p = 0.001) but was not statistically significant for N sta-
ging (p = 0.23) (Table 1). No statistically significant differ-
ence was found for Bcl-2 expression with respect to either
T staging (p = 0.59) or N staging (p = 0.52) (Table 1).
The expression of both Bax and MMP-9 differed sig-
nificantly between the PCR and PPR groups: (p = 0.003)
and (p = 0.04), respectively. This difference was not
observed for the expression of Bcl-2, cytochrome-c, or
caspase-3. The groups differed in terms of VEGF expres-
sion, but the difference was not statistically significant
(p = 0.05) (Table 2). A low level of MMP-9 was signifi-
cantly correlated with T downstaging seen between clin-
ical and pathological stagings (p = 0.04). VEGF was not
significant for T downstaging, (p = 0.05). There was no
relationship between the expression of cytochrome-c or
caspase-3 and T downstaging. None of the apoptotic or
angiogenic factors showed a statistically significant asso-
ciation with T downstaging (Table 1).
Association of apoptotic and angiogenic markers and
DFS/OS
There was no postoperative mortality. During the median
50 months of follow-up, there was no local or systemicTable 1 Relationship between Bax expression, Bcl-2 expressio
MMP-9 and T stage or N stage
Patients (n) VEGF Cy-c Casp-
T0 7 129.7 ± 67.7 68.3 ± 54.6 0.22 ±
T2-T3 22 516.51 ± 69.63 54.48 ± 28.85 0.07 ±
P value 0.051 0.72 0.19
No 19 381.4 ± 631.1 61.2 ± 38.6 0.12 ±
N(+) 10 528.67 ± 531.40 50.28 ± 28.15 0.06 ±
P value 0.20 0.68 0.21
Units: VEGF, pg/ml; Cy-c: Cytochrome-c, ng/ml; Casp-3: Caspase-3, pmol AMC/min/
*Numbers in parentheses indicate percentages.recurrence in 7 patients in the PCR group. Local or sys-
temic recurrence was observed in 8 patients in the noPCR
group (36.3%). At the end of the 50-month follow-up
period, the OS was 100 % for the PCR group and 70.1%
for the noPCR group. The 50-month DFS was 100% in
the PCR group and 64% in the noPCR group. There was
no statistically significant difference between groups
according to OS (p = 0.58) and DFS (p = 0.08).
Discussion
In locally advanced rectal cancer, preoperative chemora-
diotherapy offers improved local control, reduced tox-
icity, and higher rates of sphincter preservation without
compromising oncological outcome compared with
postoperative treatment [22]. However, neoadjuvant
treatment protocols may be inefficient in some patients.
It is important to identify which patients will respond to
neoadjuvant CRT.
Several molecular markers have been proposed as pre-
dictors of therapeutic response to CRT. However, to
date, no molecular marker has been definitively proven
to be predictive of response to CRT [5,23-31]. Garcia
et al. [32] studied 132 patients with locally advanced rec-
tal cancer treated with CRT followed by surgery. DNA
from pretreatment tumor biopsies and control DNA
from paired normal surgical specimens was screened for
mutations and polymorphisms that are individually asso-
ciated with failure to achieve a PCR after CRT. The
authors found that the combination of a KRAS mutation
with cyclin D1G870A (AA) and methylenetetrahydrofo-
late reductase (NAD[P]) C677T polymorphisms syner-
gistically identify, with a high degree of accuracy, a
subset of rectal cancer patients who do not develop a
PCR in response to CRT. In light of previous studies, we
evaluated whether apoptotic factors (Bcl-2, Bax expres-
sion, caspase-3 activity, and cytochrome-c) and angio-
genic parameters (MMP-9 levels and VEGF expression)
were correlated with the response to CRT and could
predict OS and DFS.n the expression of VEGF, Cytochrome-c, Caspase-3, or
3 MMP-9 Bax expression Bcl-2 expression
<10%—>10% <10%—>10%
0.1 488.6 ± 405.1 1(14)——6(86) 4(29)———3(20)
0.043 1166.6 ± 745.9 18(82)–4(18) 10(71)—12(80)
0.04 0.001 0.59
<10%—>10% <10%—>10%
0.2 991.4 ± 803.6 11(58)—8(42) 10(71)—9(60)
0.47 1064.97 ± 620.8 8(80)———2(20) 4(29)———6(40)
0.50 0.23 0.52
mg; MMP-9, ng/ml.
Table 2 Relationship between the response to neoadjuvant CRT and the expression of Bax, Bcl-2, Cytochrome-c,
Caspase-3, VEGF, and MMP-9
Complete response (PCR) Partial or no response (noPCR) p value
Bax
<10% 1 (14) 18 (82) 0.003
>10% 6 (86) 4 (18)
Bcl-2
<10% 4 (57) 10 (45) 0.59
>10% 3 (43) 12 (55)
Cytochrome-c 68.38 ± 54.59 54.48 ± 28.85 0.4
Caspase-3 0.22 ± 0.353 0.07 ± 0.43 0.2
VEGF 129.67 ± 67.726 516.51 ± 649.63 0.05
MMP-9 488.60 ± 405.16 1166.64 ± 745.91 0.04
Units: Cytochrome-c, ng/ml; Caspase-3, pmol AMC/min/mg; VEGF, pg/ml; MMP-9, ng/ml.
*Numbers in parentheses indicate percentages.
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form of cell death that is characterized by cytoplasmic
fragmentation and nuclear condensation, and it contri-
butes to both physiological and pathological processes
[33]. Some Bcl-2 family members induce apoptosis (Bax,
Bad, Bid, and Bcl-X1), whereas others inhibit apoptosis
(Bcl-2 and Bcl-X1). Cell homeostasis depends on a bal-
ance between these apoptotic and anti-apoptotic factors.
Chang et al. [34] reported that Bax expression was sig-
nificantly higher in a complete response group than in a
partial response group (54% versus 29%, respectively; p
= 0.017). In addition, CRT response was independent of
other clinicopathologic parameters, including age, sex,
pretreatment tumor size, distance from the anal verge,
pretreatment stage (cT or cN), and type of operation.
Tsamandas et al. [35] noted that in rectal adenocarcin-
oma, bax and bcl-2 proteins are frequently co-expressed
with p53. Co-expression of bax with p53 protein is asso-
ciated with poor clinical outcome, especially in cases
without concomitant expression of bcl-2 [35]. Nehls
et al. [36] investigated 92 rectal cancer patients treated
with preoperative radiotherapy and found that Bax pro-
tein expression may help to predict disease recurrence
in preoperatively irradiated rectal cancers, whereas ex-
pression of p53, the proposed upstream regulator of
bax-induced apoptosis, did not provide additional prog-
nostic information. In our study, bax expression was
found in 86% of patients in the complete response group
and in 18% of patients in the partial response group.
This difference is statistically significant (p = 0.001). The
results of our study, together with those of previous
studies, suggest that Bax expression is important for de-
termining the response to CRT.
The biochemical detection of caspase-3 activity is a
simple quantitative method for measuring a marker of
apoptosis in tissue samples and preoperative rectal can-
cer biopsies. The pro-apoptotic enzyme caspase-3 acts ata convergence point of the intrinsic and extrinsic apop-
tosis induction pathways; therefore, its activity should
yield a reliable measure of ongoing levels of apoptosis in
tumor samples [37]. Heer et al. [38] determined the
feasibility of measuring caspase-3 activity using 47
archived fresh-frozen preoperative biopsy samples and
corresponding resected rectal tumor specimens. Caspase-
3 activity levels were strongly correlated in preoperative
biopsies and tumor samples. The levels were significantly
higher in the tumor specimens than in the preoperative
biopsies. Heer et al. concluded that caspase-3 activity is an
important indicator of local recurrence in rectal cancer.
However, in our study, caspase-3 levels did not differ
between the PCR and noPCR groups.
In the present study, we investigated another apoptotic
marker, Bcl-2 expression. The role of Bcl-2 expression
remains controversial. Contu et al. [39] did not find any
correlation between Bcl-2 expression and age, histo-
logical grade, depth of invasion, lymphatic involvement,
distant metastasis or tumor stage. Similarly, in our study,
we found no significant relationship between Bcl-2 ex-
pression and pathologic response rate.
Matrix metalloproteinase expression and VEGF expres-
sion are the most investigated indicators in terms of the
role of angiogenesis in the pathological response. MMP-9
is a substantial matrix metalloproteinase that plays an im-
portant role in metastasis and cancer invasion, leading to
the degradation of matrix components [40,41]. In patients
with colorectal cancer, MMP-9 expression in tumor tissue
was found to be higher than that in healthy mucosa. Unsal
et al. [42] reported that MMP-9 expression in patients
with rectal cancer was correlated with poor tumor re-
sponse to preoperative CRT in their study of 44 cases. In
our study, the mean MMP-9 level was 488.60 ±
405.169 ng/ml in complete responders and 1166 ±
745.912 ng/ml in partial responders. This difference was
statistically significant (p = 0.04).
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acidic or basic fibroblast growth factor and interleukin-8
(IL-8), work together to organize the complex process
of angiogenesis. Angiogenesis is related to VEGF
over-expression in tumor cells, especially in solid
tumors [43].
Although VEGF was not detected in normal rectal mu-
cosa in recent immunohistochemical studies, significant
immunoreactivity was noted in rectal cancer tissues [43].
Wong et al. [44] studied the relationship between VEGF
expression and progression from adenoma to carcinoma,
and they emphasized that VEGF activation is an early
occurrence that may promote the initiation of angiogen-
esis. Nozue et al. [45] investigated VEGF expression in
patients with locally advanced rectal cancer before and
after neoadjuvant RT and detected intense VEGF immu-
noreactivity and numerous VEGF-positive tumors. In
the study of Zlobec et al. [46], a strong association was
found between complete tumor response and the
absence (or low levels) of VEGF expression in biopsy
samples of rectal tumors prior to RT. VEGF expression
was elevated and had notable immunoreactivity in non-
responder tumors compared with complete responder
tumors. In our study, the mean VEGF level was 516.51
± 649.634 pg/ml in the partial responder group and
129.67 ± 67.726 pg/ml in the complete responder group
(p = 0.05). In other words, our results suggest there
may be an increase in VEGF levels in the noPCR group,
similar to the findings of Zlobec et al [46].
In the present study, we also evaluated the oncological
outcomes of patients with stage III (cT3 N+) low or mid
rectal cancer. Pathological examination of the surgical
specimens revealed PCR in 7 patients (24.1%) and
noPCR in 22 patients (75.8%). Our prospective survival
analysis indicates that patients in the PCR group experi-
enced better oncological outcomes than patients in the
noPCR group. In the PCR patients, the 50-month OS
and DFS were both 100%. In the noPCR group, the 50-
month OS and DFS were 70.1% and 64%, respectively.
This difference is notable but statistically not significant
(OS, p = 0.58; DFS, p = 0.08).
Our results suggest that oncological and functional
outcomes after preoperative CRT are likely to be worse
in patients with low bax expression and high levels of
VEGF and MMP-9 upon histopathological examination
of endoscopic biopsy tissues. Survival rates are better in
PCR, on the other hand, low VEGF, MMP-9 levels and
high Bax expression is found in patients with PCR. As a
result of these findings, These parameters may be useful
in prediction of PCR and different treatment options
may be considered with the hope of increasing response
rates in this group of patients. New chemotherapy pro-
tocols may be administered to increase the likelihood of
a complete response in this group.Conclusions
In conclusion, our data confirm the existing evidence
that rectal cancer patients have a favorable long-term
outcome after preoperative CRT with a low risk of local
recurrence and distant metastasis. An analysis of these
markers may be useful for predicting the response rates
to neoadjuvant CRT. Prospective randomized studies
with large samples are needed to confirm these onco-
logical markers for predicting the response to CRT and
to design tailored neoadjuvant and adjuvant therapies on
an individualized patient basis.
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